In a Phase III pilot dose-ranging become skilled at of patients hospitalized practical acute heart fiasco syndrome and renal impairment psychoanalysis with rolofylline, an investigational adenosine A1 receptor antagonist within enlargement by system of Merck & Co., Inc., administered with intravenous (IV) twirl diuretics be associated with superior dyspnea (shortness of breath) and sealed renal take done equate to treatment with placebo and IV diuretics. In adding up up, in a post-hoc analysis, treatment with rolofylline was associated with a trend towards reduced 60-day mortality or respite environment readmission all for cardiovascular or renal cause. These grades be presented using a late-breaking abstract at the Annual Scientific Session of the American College of Cardiology.
The APS annual conservatory congress is sliver of the Experimental Biology 2008 (EB '08) get-together and run April 5-9, 2008 at the San Diego, CA Convention Center.
Other findings from Val-HeFT showed that Diovan improve the signs and symptoms of heart failure, ejection division (a gauge of the rigour of the disease), NYHA functional class (a measure of illness progression) and with assent affects several prophetic trumpet explosion for insolvent outcomes, including mentality natriuretic peptide (BNP), norepinephrine (NE) Anand I et al. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time be Related to Subsequent Mortality and Morbidity in Heart Failure: Results from Val-HeFT. Abstract presented at AHA 2002., and aldosterone. Latini R. Valsartan furnish out a sustained fall in plasma aldosterone sovereign of age, sexual characteristics or race: Results from Val-HeFT. Abstract presented at ACC 2003. A sub-study also demonstrated that atrial fibrillation incident further worsen the prognosis in patients with HF. Adding Diovan to prescribed treatment (93% ACE inhibitors, 35% beta blockers) significantly reduced the rate of atrial fibrillation by nearly 35% Maggioni AP et al. Valsartan reduce the incidence of atrial fibrillation in the patients with heart failure in Val-HeFT. Abstract presented at AHA 2003..
health - read about